重大公告
Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc Relationship to the Company (please enter “head office” or “subsidiaries”): head …
Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office …
New Appointment of Compensation Committee Member
Date of occurrence of the change: Sep 28, 2020 Name of the functional committees: Compensation committee Name and resume of the previous position holder: Chung-Ming …
TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866
1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858
1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head …